Q3 2019 Earnings Estimate for Humana Inc Issued By Svb Leerink (NYSE:HUM)

Share on StockTwits

Humana Inc (NYSE:HUM) – Svb Leerink lifted their Q3 2019 EPS estimates for shares of Humana in a report released on Monday, July 15th. Svb Leerink analyst A. Gupte now forecasts that the insurance provider will earn $5.22 per share for the quarter, up from their previous forecast of $5.15.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, May 1st. The insurance provider reported $4.48 EPS for the quarter, topping analysts’ consensus estimates of $4.30 by $0.18. The business had revenue of $16.11 billion during the quarter, compared to the consensus estimate of $15.67 billion. Humana had a net margin of 2.99% and a return on equity of 20.77%. The company’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.36 earnings per share.

A number of other equities research analysts also recently commented on HUM. SunTrust Banks lifted their price target on shares of Markel to $1,100.00 and gave the stock a “hold” rating in a report on Thursday, May 2nd. Barclays set a $24.00 price target on shares of Tenet Healthcare and gave the stock a “hold” rating in a report on Wednesday, April 17th. Credit Suisse Group reiterated a “buy” rating and set a $19.50 price target on shares of Infineon Technologies in a report on Thursday, May 2nd. Citigroup cut shares of BCE from a “buy” rating to a “neutral” rating in a research report on Thursday, May 2nd. Finally, Zacks Investment Research cut shares of Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $336.42.

Shares of NYSE HUM opened at $283.33 on Wednesday. The stock has a market capitalization of $38.39 billion, a P/E ratio of 19.47, a PEG ratio of 1.17 and a beta of 0.87. Humana has a 12 month low of $225.65 and a 12 month high of $355.88. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.40. The business’s 50-day moving average price is $261.82.

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUM. 1ST Source Bank lifted its position in Humana by 2.8% during the first quarter. 1ST Source Bank now owns 1,414 shares of the insurance provider’s stock valued at $376,000 after buying an additional 39 shares in the last quarter. One Wealth Advisors LLC lifted its position in Humana by 5.8% during the fourth quarter. One Wealth Advisors LLC now owns 731 shares of the insurance provider’s stock valued at $209,000 after buying an additional 40 shares in the last quarter. Cornerstone Advisors Inc. lifted its position in Humana by 13.5% during the second quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock valued at $94,000 after buying an additional 42 shares in the last quarter. Nachman Norwood & Parrott Inc lifted its position in Humana by 5.0% during the first quarter. Nachman Norwood & Parrott Inc now owns 1,058 shares of the insurance provider’s stock valued at $281,000 after buying an additional 50 shares in the last quarter. Finally, Kovack Advisors Inc. lifted its position in Humana by 2.6% during the first quarter. Kovack Advisors Inc. now owns 2,009 shares of the insurance provider’s stock valued at $534,000 after buying an additional 51 shares in the last quarter. 92.51% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: Elliott Wave Theory

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Continental Resources, Inc.  Given Consensus Recommendation of “Buy” by Brokerages
Continental Resources, Inc. Given Consensus Recommendation of “Buy” by Brokerages
Bruker Co.  Receives $49.20 Consensus Price Target from Analysts
Bruker Co. Receives $49.20 Consensus Price Target from Analysts
Rio Tinto plc ADR  Receives Average Rating of “Hold” from Brokerages
Rio Tinto plc ADR Receives Average Rating of “Hold” from Brokerages
Crescent Point Energy Corp  Receives Average Recommendation of “Buy” from Analysts
Crescent Point Energy Corp Receives Average Recommendation of “Buy” from Analysts
Eastgroup Properties Inc  Given Consensus Recommendation of “Hold” by Brokerages
Eastgroup Properties Inc Given Consensus Recommendation of “Hold” by Brokerages
Brokerages Set Canadian National Railway  Price Target at C$125.09
Brokerages Set Canadian National Railway Price Target at C$125.09


© 2006-2019 Ticker Report